News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
109last 24h
3129last 7d
511● bullish (7d)
313● bearish (7d)
227publishers
Barrons.com59d agoneutral
‘Miracle’ Cancer Drug Sets Revolution Medicines Up for More Market Share GainsMT Newswires59d agoneutral
Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC SaysInsider Monkey60d agobullish
Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?Investor's Business Daily60d agoneutral
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?BioPharma Dive60d agoneutral
A new immuno-oncology play raises $225M for a next-generation drug24/7 Wall St.61d agoneutral
Here’s How Much You Need Invested to Collect $1,000 a Month in DividendsBioPharma Dive61d agobullish
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapyThe Wall Street Journal61d agoneutral
Novartis Trial Failure Serves as Cautionary Tale for Pharma M&A24/7 Wall St.62d agobullish
Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock NowInsider Monkey63d agoneutral
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns RealMT Newswires65d agoneutral
Market Chatter: Bristol Myers Squibb Paused Zola-Cel Trials Over Safety ConcernsThe Wall Street Journal66d agoneutral
Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side EffectsSimply Wall St.67d agoneutral
What Does Bristol Myers Squibb (BMY) Trial Pause Mean For Its Pipeline?